Rosiglitazone evaluated for cardiovascular outcomes –– an interim analysis

Author： Bahtiyar Güül   Jean-Louis Girardin   Nessim Fiby   McFarlane Samy I  

Publisher： Future Medicine

ISSN： 1475-0708

Source： Therapy, Vol.4, Iss.5, 2007-09, pp. : 507-511

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 1462-8902, Iss. 10, 2015-10 ,pp. : 949-955

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 10, 2015-10 ,pp. : 949-955

John Wiley & Sons Inc

Access to resources Recommend Favorite

Year-by-year analysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial

By Keech Cheryl A.   Sashegyi Andreas   Barrett-Connor Elizabeth  

Current Medical Research and Opinion, Vol. 21, Iss. 1, 2005-01 ,pp. : 135-140

Informa Healthcare

Access to resources Recommend Favorite

Effect of active vitamin D on cardiovascular outcomes in predialysis chronic kidney diseases: A systematic review and meta‐analysis

By  

NEPHROLOGY, Vol. 20, Iss. 10, 2015-10 ,pp. : 706-714

John Wiley & Sons Inc

Access to resources Recommend Favorite

Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 734-739

John Wiley & Sons Inc

Access to resources Recommend Favorite